These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26946767)

  • 1. Long-Term Treatment with Olanzapine in Hospital Conditions: Prevalence and Predictors of the Metabolic Syndrome.
    Popović I; Ravanić D; Janković S; Milovanović D; Folić M; Stanojević A; Nenadović M; Ilić M
    Srp Arh Celok Lek; 2015; 143(11-12):712-8. PubMed ID: 26946767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
    L'Italien GJ; Casey DE; Kan HJ; Carson WH; Marcus RN
    J Clin Psychiatry; 2007 Oct; 68(10):1510-6. PubMed ID: 17960964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.
    Zhang C; Fang X; Yao P; Mao Y; Cai J; Zhang Y; Chen M; Fan W; Tang W; Song L
    Psychoneuroendocrinology; 2017 Jul; 81():138-143. PubMed ID: 28477447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.
    Wampers M; Hanssens L; van Winkel R; Heald A; Collette J; Peuskens J; Reginster JY; Scheen A; De Hert M
    Eur Neuropsychopharmacol; 2012 Jan; 22(1):17-26. PubMed ID: 21511441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and predictors of metabolic syndrome in patients with schizophrenia and healthy controls: A study in rural South Indian population.
    Rawat VS; Ganesh S; Bijjal S; Shanivaram Reddy K; Agarwal V; Devi R; Kumar CN; Christopher R; Thirthalli J
    Schizophr Res; 2018 Feb; 192():102-107. PubMed ID: 28454923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.
    Pallava A; Chadda RK; Sood M; Lakshmy R
    Nord J Psychiatry; 2012 Jun; 66(3):215-21. PubMed ID: 22017264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics.
    Krane-Gartiser K; Breum L; Glümrr C; Linneberg A; Madsen M; Køster A; Jepsen PW; Fink-Jensen A
    Nord J Psychiatry; 2011 Oct; 65(5):345-52. PubMed ID: 21428861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders.
    Abdel Aziz K; Mohd Ahmed H; Stip E; Aly El-Gabry D
    Int Clin Psychopharmacol; 2024 Jul; 39(4):257-266. PubMed ID: 38381917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome and cardiovascular risk among institutionalized patients with schizophrenia receiving long term tertiary care.
    Seow LS; Chong SA; Wang P; Shafie S; Ong HL; Subramaniam M
    Compr Psychiatry; 2017 Apr; 74():196-203. PubMed ID: 28214752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
    Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
    Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
    Saddichha S; Manjunatha N; Ameen S; Akhtar S
    J Clin Psychiatry; 2007 Nov; 68(11):1793-8. PubMed ID: 18052574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
    Alméras N; Després JP; Villeneuve J; Demers MF; Roy MA; Cadrin C; Mottard JP; Bouchard RH
    J Clin Psychiatry; 2004 Apr; 65(4):557-64. PubMed ID: 15119921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
    Henderson DC; Copeland PM; Borba CP; Daley TB; Nguyen DD; Cagliero E; Evins AE; Zhang H; Hayden DL; Freudenreich O; Cather C; Schoenfeld DA; Goff DC
    J Clin Psychiatry; 2006 May; 67(5):789-97. PubMed ID: 16841629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia.
    Lu ML; Chen CH; Kuo PT; Lin CH; Wu TH
    Schizophr Res; 2018 Mar; 193():139-145. PubMed ID: 28720417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].
    Rubio G; Gómez-de-la-Cámara A; Ledesma F; Burón JA; Rodríguez-Morales A; Martínez-Junquera G;
    Med Clin (Barc); 2006 Apr; 126(12):441-4. PubMed ID: 16620729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.